TUCSON, Ariz.--(BUSINESS WIRE)--The Critical Path Institute (C-Path) and Ventana Medical Systems, Inc. (Ventana) (NASDAQ: VMSI) today released additional information about C-Path’s $2.1 million grant from Science Foundation Arizona (SFAz) to fund a collaboration project with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to develop a standard testing and evaluation process for companion diagnostics and their associated targeted cancer therapies. Currently, there is no proven development pathway for FDA approval of the necessary companion diagnostic tests and their associated targeted therapies. The goal of this collaboration is to establish the performance standards that would serve as the model for future FDA co-submissions of these companion diagnostic tests and their targeted drug therapies. With the SFAz grant, C-Path and Ventana will work closely with the FDA and NCI to apply these standards to one of Ventana’s in-process companion diagnostic tests for lung cancer.
